Reconstructing Oetzi’s, The Neolithic Man Family Tree with 454 Sequencing

PENZBERG, Germany--(BUSINESS WIRE)--Since Oetzi’s sensational discovery, in 1991 and his extraction from the glacier in Alto Adige in Italy, Europe’s most famous mummy has been the subject of intensive scientific study. The initial research focused on dating the mummy, and with the aid of radiocarbon dating analyses it has been established that Oetzi dates back to around 3,000 BC. Oetzi the Neolithic man is assumed to have been a hunter or a high-ranking warrior and the cause of his death, according to the most accredited hypothesis was an arrow wound. Currently, Dr. Gianluca De Bellis of the CNR Institute of Biomedical Technology is taking part in new investigations promoted by Professor Franco Rollo of the University of Camerino. De Bellis is analyzing Oetzi´s mitochondrial DNA by means of ultrafast 454 sequencing.

“The Genome Sequencer FLX from Roche Diagnostics has made a significant contribution in the simplification and optimization of DNA testing. Compared to traditional methods, it has increased productivity 1,000-fold, considerably reducing time investment and costs. A vast number of nucleotide sequences, the “bricks”

Previous studies that were conducted by means of traditional technologies have determined that Oetzi’s mitochondrial DNA does not resemble any sub-type found in any present existing ethnic group. In using the Genome Sequencer FLX System, it will now be possible to shed more light on the subject of Oetzi’s descendents, and establish his place in the genetic scenario of the present European race. Furthermore, 454 Sequencing data will enable researchers to trace Oetzi’s ancestors; and reconstruct an accurate phylogenetic family tree, obtaining an authentic global view of human evolution. In comparison to chromosomal DNA, which is protected within the cell nucleus, Mitochondrial DNA has far greater molecular variability; this is due to the influence of the external environment. Therefore, as apposed to its nuclear counterpart, mitochondrial DNA is far better suited for tracing evolutionary changes.

“The Genome Sequencer FLX from Roche Diagnostics has made a significant contribution in the simplification and optimization of DNA testing. Compared to traditional methods, it has increased productivity 1,000-fold, considerably reducing time investment and costs. A vast number of nucleotide sequences, the “bricks” that make up the DNA, can now be analyzed simultaneously.” explains Dr. De Bellis. He expects to finish sequencing of the DNA in the first half of 2008.

Following the mitochondrial analyses, De Bellis plans to study Oetzi’s eating habits. Tissue samples that have been extracted from the mummy’s colon will enable an analysis of his intestinal flora. The reason for this investigation will be to compare the genes between the embryonic digestive tube bacteria of Neolithic man with those of the present day modern man.

Marco Deambrosis, Head of Roche Applied Science Italy, commented: “It is a great pleasure to see that the technology of Roche Applied Science helps the scientific community in grasping a better understanding our own species. It is part of our vision to serve researchers, to support users and to share their ambitious projects with an innovative genomics approach as we did with CNR institute in Milan with the Genome Sequencer FLX System”.

For more information on 454 sequencing, visit www.roche-applied-science.com/sis/ sequencing.

About Roche

Headquartered in Basel, Switzerland, Roche is one of the world’s leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world’s biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people’s health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, a market leader in virology and active in other major therapeutic areas such as autoimmune diseases, inflammation, metabolism and central nervous system. In 2006 sales by the Pharmaceuticals Division totaled 33.3 billion Swiss francs, and the Diagnostics Division posted sales of 8.7 billion Swiss francs. Roche employs roughly 75,000 worldwide and has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai. Roche’s Diagnostics Division offers a uniquely broad product portfolio and supplies a wide array of innovative testing products and services to researchers, physicians, patients, hospitals and laboratories world-wide. For further information, please visit our website at www.roche.com.

454, 454 Sequencing and Genome Sequencer are trademarks of 454 Life Science Corporation,

Branford, CT, US.

All brands or product names are trademarks of their respective holders.